Shots:
- Eli Lilly has entered into a collaboration & license agreement with Gate Bioscience to identify, develop, & commercialize molecular gate drugs, leveraging Gate’s molecular gate drug discovery engine
- As per the deal, Gate will receive ~$856M in total, incl. an upfront payment, equity investment, & development, regulatory, & commercial milestones, along with tiered royalties on global sales
- Also, Gate can access preclinical R&D support from Lilly ExploR&D, part of Lilly Catalyze360, for its internal programs
Ref: Businesswire | Image: Eli Lilly & Gate Bio | Press Release
Related News:- Eli Lilly Receives the Health Canada’s Approval for Omvoh (Mirikizumab) to Treat Crohn’s Disease (CD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
